Filing Flows › Health Catalyst (HCAT) › Stock forecast & fair value
Health Catalyst (HCAT) stock forecast and fair value
Health Catalyst (HCAT) trades at $1.77. 3 analysts' median price target is $1.80 (+2%), from $1.50 to $2.00. Across 12 valuation methods the middle fair value is $3.34 (+89%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $5.21 | $8.53 | $23.77 | +382% |
| EV/Sales vs peers, weighted | $14.45 | $25.02 | $38.32 | 14× |
| EV/Sales vs peers, growth & margin adjusted | $3.23 | $6.31 | $11.80 | +256% |
| Residual income | −$1.24 | −$1.25 | −$1.26 | -171% |
| Analysts' price targets | $1.50 | $1.77 | $2.00 | -0.2% |
| Shareholder yield (dividends + buybacks) | $0.75 | $0.84 | $0.96 | -52% |
| Tangible book (asset value) | $0.36 | $0.45 | $0.45 | -74% |
| Survival-weighted value | $0.85 | $1.18 | $2.70 | -33% |
| Stage-weighted value (decline / turnaround) | $2.11 | $3.34 | $8.83 | +89% |
| Combined forecast (3 months) | $1.45 | $1.84 | $2.28 | +4% |
Health Catalyst's latest quarter
Health Catalyst, Q3 2026: revenue $56.3M (-26% year over year), operating margin 89.1%, net earnings $40.5M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for HCAT stock?
The median of 3 analysts' 12-month targets is $1.80, +2% from $1.77; the range is $1.50 to $2.00. The average rating is none.
What is Health Catalyst's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$1.25 and $25.02, with a middle value of $3.34 against a price of $1.77. Each method's assumptions are on the page.
Does Health Catalyst usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is HCAT stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.